Clinical Chemistry
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Clinical Chemistry 46: 1492-1493, 2000;
This Article
Right arrow Extract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Morimoto, K.
Right arrow Articles by Inouye, K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Morimoto, K.
Right arrow Articles by Inouye, K.
(Clinical Chemistry. 2000;46:1492-1493.)
© 2000 American Association for Clinical Chemistry, Inc.


Abstracts of Oak Ridge Posters

Application of Bispecific F(ab') Fragments Prepared from IgMs against Carcinoembryonic Antigen and Alkaline Phosphatase

Koichi Morimoto1,a and Kuniyo Inouye2

1 Department of Biotechnological Science, Kinki University, 930 Nishi-mitsuya, Uchita, Naga-gun, Wakayama 649-6493, Japan

2 Division of Applied Life Sciences, Graduate School of Agriculture, Kyoto University, Kyoto 606-8502, Japan
a author for correspondence: fax 81-736-77-4754, e-mail morimoto{at}bio.waka.kindai.ac.jp

Bispecific monoclonal antibodies (BsMAbs) have two different binding regions that simultaneously recognize two different antigens (1)(2). BsMAbs have been studied for use in immunodiagnosis (3)(4) and immunotherapy (5)(6).

Most BsMAbs are derived from the IgG class, whereas most hybridomas raised against carbohydrate antigens, including the tumor-associated antigens, are IgM MAb producers. IgM antibody-enzyme conjugates are of limited use in enzyme immunoassays because of steric effects, reduction of their activities, and high nonspecific binding. For these reasons, BsMAbs prepared from IgM MAbs have been especially used for cancer immunodiagnosis. Their production by hybrid-hybridoma fusion is one method (7), but it is not an effective one. F(ab') fragments have been successfully prepared from their IgMs, and their performance has been evaluated (8)(9)(10)(11). In this report, homogeneous bispecific F(ab') fragments (BsFµ fragments) were efficiently prepared from IgMs.

Mouse IgM monoclonal antibodies 9CA10 and APM05 recognize carcinoembryonic antigen (CEA) and calf intestine alkaline phosphatase (AP), respectively. Their F(ab') fragments were prepared by pepsin digestion and purified by hydrophobic interaction HPLC (8)(10)(11). The purities of the fragments from the IgMs were >96% by size exclusion HPLC using a TSKgel G3000SWXL column (7.8 mm i.d x 30 cm; Tosoh), and the yields were 54% (APM05) and 53% (9CA10), respectively. The F(ab') of 9CA10 was reduced to Fab'µ-SH with 50 mmol/L 2-mercaptoethylamine (Sigma) in phosphate-buffered saline (PBS) containing 10 mmol/L EDTA at 37 °C for 1 h, and was separated from 2-mercaptoethylamine by size exclusion HPLC on a TSKgel G3000SWXL column. Immediately after HPLC, the Fab'µ-SH was converted to a thionitrobenzonic acid (TNB) derivative with dithionitrobenzene, and Fab'µ-TNB was applied to a TSKgel G3000SWXL column to remove any excess TNB and dithionitrobenzene. Fab'µ-TNB (9CA10) was reacted with Fab'-SH (APM05) to form SS bonds between Fab'µ (9CA10) and Fab'µ (APM05) at a molar ratio of 2.5:1, followed by incubation at 4 °C for 16 h under N2 gas. Ammonium sulfate (70% saturation) was added to the reaction mixture, and the mixture was centrifuged at 10 000g for 20 min. The precipitate was dissolved with 50 mmol/L phosphate buffer (pH 7.4) containing 2.0 mol/L ammonium sulfate. The solution was applied to a TSKgel Ether-5PW column (7.5 mm i.d. x 7.5 cm; Tosoh) equilibrated with the same buffer and eluted with a linear gradient of ammonium sulfate from 2.0 to 0 mol/L at a flow rate of 0.5 mL/min. Three peaks were eluted at 32 min (peak 1), 40 min (peak 2), and 46 min (peak 3). The proteins of peaks 1 and 3 were Fab'µ-TNB and Fab'µ-SH, respectively. The protein eluted in peak 2 showed immunoreactivities against both antigens (data not shown) and was identified as BsFµ. The elution time of peak 2 suggests that the hydrophobicity of the BsFµ fragment is the average of those of the parental F(ab') fragments. The BsFµ fragments were purified to homogeneity in a one-step procedure using hydrophobic interaction HPLC (Fig. 1A ), and the final yields of the BsFµ fragments were 35–40% of the theoretical values.



View larger version (22K):
[in this window]
[in a new window]
 
Figure 1. Purification of BsFµ by hydrophobic interaction HPLC with TSKgel Ether-5PW (A), and the immunoreactivity of BsFµ against CEA (B).

(A), elution was monitored by measuring absorbance at 280 nm. The BsFµ peak is indicated by an arrow. (B), 100 µL of anti-CEA IgM covalently labeled with AP ({square}), anti-CEA F(ab') fragment covalently labeled with AP ({circ}), or BsFµ bound to AP ({triangleup}) was added to the well, followed by the addition of 100 µL of CEA solution at the concentration indicated on the x axis. p-Nitrophenylphosphate was added, and the absorbance at 405 nm was measured.

Sodium dodecyl sulfate-polyacrylamide gel electrophoresis was performed in a 6% slab gel under nonreducing conditions (12), and the proteins were stained with Coomassie Brilliant Blue R-250. The BsFµ fragment and its parental F(ab') fragments showed a similar migration pattern (144–146 kDa) during SDS-PAGE, suggesting that the BsFµ is composed of four chains [two pairs of a truncated heavy chain and an intact light chain derived from the parental F(ab')].

The dissociation constants (KD) of the BsFµ and its parental F(ab') fragments with their specific antigens were measured by surface plasmon resonance using a BIAcore biosensor (Pharmacia Biosensor). The BsFµ and its parental F(ab') fragments were injected separately and immobilized on the chip coated with goat anti-mouse (IgG + IgM) antibodies (Jackson ImmunoResearch Laboratories). When CEA (50 mg/L; Scripps Laboratories) was injected on the chips coated with BsFµ or its parental F(ab') fragments, the intensities increased 29 and 30 relative response units, respectively. The intensities of BsFµ (50 mg/L) and its parental F(ab') fragments (50 mg/L) against AP increased 23 and 24 relative response units, respectively. For CEA, the KDs were 249 nmol/L (BsFµ) and 212 nmol/L [F(ab') (9CA10)], respectively. The KDs against AP were 13 nmol/L (BsFµ) and 10 nmol/L [F(ab') (APM05)], respectively.

The immunoreactivity of BsFµ bound to AP was evaluated by sandwich enzyme immunoassay and compared with that of the F(ab') covalently conjugated to AP. A 96-well microtiter plate (Nunc-intermed; MaxiSorp) was coated with goat anti-CEA polyclonal antibody (prepared in our laboratory) and blocked by incubation with 2 g/L bovine serum albumin in PBS (pH 7.4). After washing, the plate was incubated at 25 °C for 60 min with 100 µL of CEA at various concentrations (0, 25, 50, 100, 200, 400 µg/L) and 100 µL of the BsFµ bound to AP (absorbance at 280 nm in PBS = 0.004), IgM covalently labeled with AP (absorbance at 280 nm in PBS = 0.002), or F(ab') covalently labeled with AP (A280 nm in PBS = 0.004). After another washing, 100 µL of the substrate solution (2 g/L p-nitrophenylphosphate in 50 mmol/L carbonate buffer, pH 9.5, containing 10 mmol/L MgCl2) was added to the plate for 20 min at 25 °C, and the reaction was terminated by adding 100 µL of 0.5 mol/L NaOH. The AP activity was measured by the absorbance at 405 nm (Fig. 1BUp ). The detection limits of the CEA assay (defined as 2 SD above the zero concentration calibrator) were 0.90 µg/L for BsFµ and 3.4 µg/L for F(ab'), respectively. The immunoreactivity of BsFµ against CEA was almost the same as that of the F(ab') covalently labeled with AP in the range 0.90–400 µg/L. The nonspecific binding of BsFµ was 27% (0.90 x 100/3.4 = 27) lower than that of F(ab').

Because the covalently labeled conjugate that was prepared from F(ab') and AP is a complex polymer molecule and has multiple antigen binding sites in one conjugate molecule, the conjugate cannot bind to the antigen at a molar ratio of 1:1. The BsFµ bound to the AP conjugate can bind more efficiently to the antigen at a 1:1 molar ratio. To detect lower concentrations of the antigen, BsFµ may be more useful than the covalently labeled conjugate. The BsFµ bound to the AP conjugate was stable for at least 3 months at 4 °C.

In conclusion, we showed that homogeneous BsFµ fragments prepared from IgMs recognized both antigens without any loss in immunoreactivity. The BsFµ bound to AP allowed sensitive and reliable measurement of the antigen and may be generally applicable for immunodiagnosis.


References

  1. Milstein C, Cuello AC. Hybrid hybridomas and their use in immunohistochemistry. Nature 1983;305:537-540.[Medline] [Order article via Infotrieve]
  2. Brennan M, Davison PF, Paulus H. Preparation of bispecific antibodies by chemical recombination of monoclonal immunoglobulin G1 fragments. Science 1985;229:81-83.[Abstract/Free Full Text]
  3. Suresh MR, Cuello AC, Milstein C. Advantages of bispecific hybridomas in one-step immunocytochemistry and immunoassays. Proc Natl Acad Sci U S A 1986;83:7989-7993.[Abstract/Free Full Text]
  4. Morimoto K, Inouye K. A sensitive enzyme immunoassay of human thyroid-stimulating hormone (TSH) using bispecific F(ab')2 fragments recognizing polymerized alkaline phosphatase and TSH. J Immunol Methods 1997;205:81-90.[Web of Science][Medline] [Order article via Infotrieve]
  5. Posey JA, Raspet R, Verma U, Deo YM, Keller T, Marshall JL, et al. A pilot trial of GM-CSF and MDX-H210 in patients with erbB-2-positive advanced malignancies. J Immunother 1999;22:371-379.
  6. Koelemij R, Kuppen PJ, van de Velde CJ, Fleuren GJ, Hagenaars M, Eggermont AM. Bispecific antibodies in cancer therapy, from the laboratory to the clinic. J Immunother 1999;22:514-524.
  7. Takahashi M, Fuller SA. Production of murine hybrid-hybridomas secreting bispecific monoclonal antibodies for use in urease based immunoassays. Clin Chem 1988;34:1693-1696.[Abstract/Free Full Text]
  8. Morimoto K, Inouye K. Method for the preparation of bispecific F(ab') fragments from mouse monoclonal antibodies of the immunoglobulin M class and characterization of the fragments. J Immunol Methods 1999;224:43-50.[Web of Science][Medline] [Order article via Infotrieve]
  9. Morimoto K, Inouye K. Flow cytometric analysis of sialyl Lewis A antigen on human cancer cells by using F(ab') fragments prepared from a mouse IgM monoclonal antibody. Cytotechnology 1997;24:219-226.
  10. Inouye K, Morimoto K. Single-step purification of F(ab') fragments of mouse monoclonal antibodies (immunoglobulins M) by hydrophobic interaction high-performance liquid chromatography using TSKgel Ether-5PW. J Biochem Biophys Methods 1993;26:27-39.[Web of Science][Medline] [Order article via Infotrieve]
  11. Inouye K, Morimoto K. Preparation of F(ab') fragments from rat IgM monoclonal antibodies and their application to the enzyme immunoassay of mouse interleukin-6. J Immunol Methods 1994;171:239-244.[Web of Science][Medline] [Order article via Infotrieve]
  12. Laemmli UK. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 1970;227:680-685.[Medline] [Order article via Infotrieve]




This Article
Right arrow Extract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Morimoto, K.
Right arrow Articles by Inouye, K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Morimoto, K.
Right arrow Articles by Inouye, K.


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS